[Clinical efficacy observation of omalizumab on patients with moderate to severe allergic asthma for one year].

Xu, Y; Zhou, D X; Hu, P; Gong, P H

Xu, Y; Zhou, D X; Hu, P; Gong, P H.

Affiliation

Xu Y; Pulmonary and Critical Care Medicine, Beijing Jishuitan Hospital, Beijing 100035, China.
Zhou DX; Pulmonary and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China.
Hu P; Pulmonary and Critical Care Medicine, Beijing Jishuitan Hospital, Beijing 100035, China.
Gong PH; Pulmonary and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China.

Zhonghua Yu Fang Yi Xue Za Zhi ; 57(3): 427-432, 2023 Mar 06.

Article in Zh | MEDLINE | ID: mdl-36922178

Subject(s)

Anti-Asthmatic Agents; Asthma; Humans; Omalizumab/therapeutic use; Anti-Asthmatic Agents/therapeutic use; Retrospective Studies; Bronchodilator Agents/therapeutic use; Asthma/drug therapy; Asthma/diagnosis; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Anti-Asthmatic Agents Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: Zh Journal: Zhonghua Yu Fang Yi Xue Za Zhi Year: 2023 Document type: Article

Fulltext

XML

PubMed Links

Search on Google